Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein.
about
Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein bindingImportant role of CYP2J2 in protein kinase inhibitor degradation: a possible role in intratumor drug disposition and resistancePhase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizatiPhase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).Evaluation of self-reported progression and correlation of imatinib dose to survival in patients with metastatic gastrointestinal stromal tumors: an open cohort studyEfficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors.Monitoring response and resistance to treatment in chronic myeloid leukemia.Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failureEfficacy of imatinib dose escalation in Chinese gastrointestinal stromal tumor patients.Cancer pharmacotherapy: 21st century 'magic bullets' and changing paradigms.CYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia Patients.Human hepatocyte assessment of imatinib drug-drug interactions - complexities in clinical translation.Simultaneous quantification of imatinib and its main metabolite N-demethyl-imatinib in human plasma by liquid chromatography-tandem mass spectrometry and its application to therapeutic drug monitoring in patients with gastrointestinal stromal tumor.Semi-Mechanism-Based Population Pharmacokinetic Modeling of the Hedgehog Pathway Inhibitor VismodegibRelationship of imatinib-free plasma levels and target genotype with efficacy and tolerability.Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumoursManagement of imatinib-resistant patients with chronic myeloid leukemia.Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia.A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol.Clinical implications of repeated drug monitoring of imatinib in patients with metastatic gastrointestinal stromal tumour.Prospective Analysis in GIST Patients on the Role of Alpha-1 Acid Glycoprotein in Imatinib ExposureCorrelations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing?Does the small tyrosine kinase inhibitor Imatinib mesylate counteract diabetes by affecting pancreatic islet amyloidosis and fibrosis?Therapeutic drug monitoring of targeted anticancer therapy.Population Pharmacokinetics of Imatinib in Nigerians With Chronic Myeloid Leukemia: Clinical Implications for Dosing and Resistance.A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumor.Suppression of carboxylesterases by imatinib mediated by the down-regulation of pregnane X receptor.Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels.Optimization of radotinib doses for the treatment of Asian patients with chronic myelogenous leukemia based on dose-response relationship analyses.Population Pharmacokinetic Analysis of the Oral Absorption Process and Explaining Intra-Subject Variability in Plasma Exposures of Imatinib in Healthy Volunteers.Imatinib plasma levels: correlation with clinical benefit in GIST patients.Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia.A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer.Should therapeutic drug monitoring of the unbound fraction of imatinib and its main active metabolite N-desmethyl-imatinib be developed?Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib.A Selective Biligand Inhibitor of CK2 Increases Caspase-3 Activity in Cancer Cells and Inhibits Platelet Aggregation.Variability and singularity arising from poor compliance in a pharmacokinetic model II: the multi-oral case.Pharmacology and pharmacokinetics of imatinib in pediatric patients.Compliance spectrum as a drug fingerprint of drug intake and drug disposition.
P2860
Q24602935-34D94D37-2086-4AF6-AA95-DFA9EEEAE431Q28538733-703D559E-2A9D-4FE5-9C64-0C8B21509A23Q30357011-CD084E48-AAC6-4FE1-9F16-D263D7CE6F0BQ33574578-B01C116C-6BF1-4C24-9945-89391E5D9608Q33756542-98215EFA-6E35-4BE4-9398-53C8975F426BQ34339623-11A62F8A-8010-4275-B1F6-52AAB3C58724Q34761663-D85E3CC8-07DB-4154-BF08-A7ABD7237C79Q35596200-7ED742BB-521D-4A1B-9D58-9301A25012A6Q35761718-D47681F5-0463-4C60-8CFD-36A270B42399Q35827640-1EAEEDC1-26FA-46F7-89C9-D27E780A773BQ36229161-65E36F5D-53AA-4470-822E-3AD016E780D4Q36243653-786F83D6-11EB-4F9C-9BF2-6A91EE8F361BQ36407123-787C94BC-AEFA-4023-83F1-5286BEA08529Q36473104-E138DF9B-638B-4649-83E4-F161B182B2F5Q36667469-26B33B89-7678-44D4-9C4B-B7BBA3F73BC7Q36729934-A609B52C-0A39-44D8-B858-9AE390158DF4Q36776423-DCAE4CB1-D0CF-4DF9-9BB0-6E92C7881E0CQ36792630-DE63411A-F494-4CDC-AF6C-E143E8852F14Q37354482-9B939474-2992-4A90-90E4-26F06D87B077Q37504935-0A3E909F-B832-4CCC-B128-6799D797AE0BQ37650706-C3E9D8EC-DEF7-4634-8C6A-E94870F0FB16Q37731289-975E9889-7385-4597-B24A-06642917E390Q38045474-8D0115E5-42F4-46C8-BB1C-418B67846FD4Q38579278-BDE763EA-EE2D-4CF0-9031-D2E087F44F28Q38724254-BF05C9D2-2F3B-4A0B-9858-7E11DDD962C2Q38729029-E98CA046-0257-4123-86E6-BFEB3A49D383Q38995804-6D2E564C-56AA-45C3-A068-29471D45901CQ39651800-E83C82E6-8C32-4008-A853-CA3B2FAB3E1FQ40213114-489A3011-2BF4-4B84-8F76-FC704E86C5D6Q40721053-76B6CB79-51D8-4457-B6E2-A0AF7AE4A5BAQ42843116-63FF9F97-A6BC-4EA4-8F4A-CC807ABA8C4CQ43841175-2A058A0F-C770-453B-BDF3-3DACBBA93B29Q44027139-D5AEAD82-0DF9-4147-AD0E-6556BBF2B638Q44533503-11C74DAC-3CBC-4010-90A3-9766AACF4C63Q45403481-50323EA9-9CB6-4F3C-A21A-69C46BC03EC5Q47847397-176BDBD8-FA65-4668-BD27-28C30CC185F5Q47911433-FB8CE1A0-46F7-4C05-B0DF-7766C221A13BQ48154210-53BA915C-4BD6-4B66-A7E7-20A58CEF8E3EQ50094239-9C7D7977-6702-4D24-9BDF-2F027B0DD4C8Q51286554-FADA1048-F7B6-46EC-B40B-0599BFB915C5
P2860
Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein.
@ast
Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein.
@en
type
label
Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein.
@ast
Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein.
@en
prefLabel
Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein.
@ast
Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein.
@en
P2093
P2860
P50
P1476
Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein.
@en
P2093
A Rosselet
L A Decosterd
M A Duchosal
P2860
P304
P356
10.1111/J.1365-2125.2006.02719.X
P407
P577
2006-07-01T00:00:00Z